FDA approves first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU October 12, 2022
KEYTRUDA® Receives Four New Approvals in Japan, Including in High-Risk Early-Stage TNBC October 5, 2022
FDA approved Lytgobi (futibatinib) for adults with advanced intrahepatic cholangiocarcinoma (iCCA) who have FGFR2 gene fusions or other rearrangements October 5, 2022
FDA Approves Retevmo® (selpercatinib) for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type September 28, 2022
European Commission approves Opdualag (nivolumab + relatlimab) for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1% September 28, 2022
Lynparza approved in China as 1L maintenance treatment with bevacizumab for HRD+ve advanced ovarian cancer September 28, 2022
Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer September 13, 2022
FDA Approves Pemazyre® (Pemigatinib) For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement September 7, 2022
Imfinzi plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced BTC September 7, 2022
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence June 14, 2022
FDA approves Kymriah® CAR-T cell therapy for adult patients with R/R follicular lymphoma June 13, 2022
